Grapiprant Galliprant in Dogs

Grapiprant, sold under the brand name Galliprant, is a prescription NSAID used in dogs to help control pain and inflammation from osteoarthritis. It is approved for oral use in dogs and is commonly chosen when a dog has stiffness, slowing down on walks, trouble rising, reluctance to jump, or other signs that fit chronic joint pain. It does not cure arthritis or rebuild cartilage, but it can improve comfort and day-to-day mobility when it matches the dog’s overall health picture.

What makes Galliprant different from many older NSAIDs is that it targets one specific prostaglandin receptor involved in pain and inflammation rather than broadly blocking cyclooxygenase enzymes. In practice, that means some dogs tolerate it well, while others still develop stomach upset or other adverse effects and need a different plan. Your vet will decide whether it fits your dog’s age, weight, medical history, and other medications.

Galliprant is not a medication pet parents should start, stop, or combine on their own. Dogs under 8 pounds cannot be accurately dosed with the labeled tablets, and safe use has not been established in dogs younger than 9 months or in breeding, pregnant, or nursing dogs. Long-term arthritis care also usually involves more than one tool, so your vet may pair medication with exercise changes, body-weight support, rehab, or other pain-control options.

Galliprant works by blocking the EP4 receptor for prostaglandin E2, a signaling pathway strongly involved in osteoarthritis pain and inflammation. Traditional NSAIDs usually reduce prostaglandin production by inhibiting COX enzymes. Grapiprant works farther downstream, at the receptor level, which is why it is often described as a more targeted NSAID option.

That targeted action matters because prostaglandins do more than create pain. They also help support normal functions in the stomach, kidneys, blood flow, and other tissues. By focusing on EP4, grapiprant aims to reduce pain signaling while affecting fewer prostaglandin pathways than many older NSAIDs. That does not mean it is risk-free. It still has NSAID-type cautions, still requires a prescription, and still needs monitoring in dogs using it long term.

After an oral dose, the medication is absorbed fairly quickly, and many dogs begin showing effect within hours, though the real-world improvement a pet parent notices may take longer and depends on the severity of arthritis. Galliprant is best thought of as one part of a mobility plan, not a stand-alone fix. If a dog still struggles despite treatment, your vet may discuss dose review, a different NSAID, add-on pain medications, rehab, or injectable options such as monoclonal antibody therapy.

The most commonly reported side effects with Galliprant are digestive. These include vomiting, diarrhea, soft stool, decreased appetite, mucus in the stool, and lethargy. In the field study summarized in the FDA labeling, vomiting and diarrhea or soft stool were among the most frequent adverse reactions. Some dogs also had lower albumin or total protein values, which is one reason your vet may recommend bloodwork during longer treatment courses.

Even though Galliprant is often discussed as a more targeted NSAID, pet parents should still watch for the same kinds of warning signs they would watch for with other arthritis medications. Call your vet promptly if your dog stops eating, vomits repeatedly, develops black or bloody stool, seems weak, becomes unusually sleepy, or seems worse instead of better. If your dog gets too much medication, overdose signs can include vomiting, appetite loss, and stool changes.

Serious reactions are less common, but they matter. Dogs with prior drug sensitivities, significant organ disease, or complicated medication lists may need a different plan or closer monitoring. For chronic arthritis care, your vet may recommend baseline bloodwork and urinalysis before starting treatment, then periodic rechecks to look at liver, kidney, protein, and overall tolerance over time.

Galliprant is labeled at 0.9 mg per pound, which is 2 mg per kilogram, by mouth once daily. The labeled tablets come in 20 mg, 60 mg, and 100 mg strengths. Only the 20 mg and 60 mg tablets are scored, and the FDA client sheet notes that dosing should be calculated in half-tablet increments. Dogs under 8 pounds cannot be accurately dosed with the labeled tablets.

Galliprant may be given with or without food. Absorption is better on an empty stomach, but if your dog vomits or seems nauseated when it is given that way, your vet may advise giving future doses with food or a small treat. Do not crush, split, or substitute tablet sizes unless your vet specifically instructs you to do so, especially with the 100 mg tablet, because the labeling notes that breaking the 100 mg tablet in half does not guarantee an accurate half-dose.

If you miss a dose, give it when you remember unless it is close to the next scheduled dose. In that case, skip the missed dose and return to the regular schedule. Do not double up. For long-term use, your vet will usually aim for the lowest effective dose and shortest duration that still keeps your dog comfortable, while reassessing whether the medication is still helping enough to justify ongoing use.

Galliprant should not be combined with other NSAIDs or corticosteroids unless your vet has a very specific reason and monitoring plan. Stacking anti-inflammatory drugs can raise the risk of stomach ulceration, bleeding, kidney stress, and other complications. That means pet parents should tell your vet about every medication and supplement a dog receives, including aspirin, prednisone, carprofen, meloxicam, deracoxib, fish oil products, joint supplements, and over-the-counter human medications.

The FDA labeling also notes that concurrent use with other highly protein-bound drugs has not been studied in dogs. Because grapiprant is a P-glycoprotein substrate, some dogs with MDR1 gene mutations may need extra caution. PetMD specifically flags this concern in Collies, Shelties, Australian Shepherds, and related breeds. That does not automatically rule the drug out, but it does make a complete medication and breed history more important.

Many dogs with osteoarthritis need combination care. Cornell notes that dogs with OA may receive additional medications such as gabapentin or amantadine alongside NSAIDs, and some dogs may move to or add monthly monoclonal antibody therapy. Those combinations should always be guided by your vet, because the right plan depends on pain severity, mobility goals, bloodwork, and how well your dog tolerates each option.